Jazz Pharmaceuticals PLC
(NAS:JAZZ)
$
121.58
-0.01 (-0.01%)
Market Cap: 7.35 Bil
Enterprise Value: 10.93 Bil
PE Ratio: 17.12
PB Ratio: 1.76
GF Score: 85/100 Jazz Pharmaceuticals PLC at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 11, 2021 / 05:15PM GMT
Release Date Price:
$173.8
(-1.31%)
Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research
Good day, everybody, and thanks for joining us at the Bank of America Annual Healthcare Conference. I'm -- biotech analyst and spec pharma analyst, and I'm pleased to be introducing our next company presenting, Jazz Pharmaceuticals.
We've got the team here. We've got Kim Sablich, General Manager of North America; Robert Iannone, EVP of R&D and CMO. And we've got the 2 CEOs. We've got Bruce Cozadd from Jazz, and we've got Justin Gover from GW Pharmaceuticals.
So first off, thanks, everybody, for joining us today.
Bruce C. Cozadd
Jazz Pharmaceuticals plc - Co-Founder, Chairman & CEO
Yes. Great to be with you, Jason.
Questions & Answers
Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research
So timely, we just have the -- a big acquisition close with the GW Pharma deal closing, I guess, last week. So maybe Bruce as just a softball starter to the conversation. Maybe
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot